— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs

Get full access to the platform from any device & via Cbonds app

Enhance your portfolio management with Cbonds Excel Add-in

Build yield maps, make chart comparison within a click

Don't wait any longer — start using Cbonds today! Register

MAIA Biotechnology: Nonreliance On Previously Issued Financial Statements Or Related Audit Report Or Completed Interim Report

February 3, 2023 U.S. Securities and Exchange Commission

Show full article

This functionality is available for registred users only

Issuer — MAIA Biotechnology

Full name

MAIA Biotechnology, Inc.
Registration country

USA
Industry

Pharmaceutical Preparation and Biotechnology
М/S&P/F

*** / *** / ***

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

Evaluate advanced analytical tools
Get full online access to the database
Try our powerful bond screener
Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Other Company's News

Try in 7-days Trial access

Free for company representative

Get full online access to the database
Use our powerful bond screener
Track bond prices from 400+ sources
Smart Portfolio Monitoring
Evaluate advanced analytical tools

Why Cbonds?

24 Years of Market Leadership
Trusted by clients across 90 countries for decades of reliable service
Used by Financial Professionals & Fintech central banks, asset managers, fintech innovators
Convenient platform for private investors for informed investment decisions